Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent IDH Mutated High-Grade Gliomas
NCT03925246Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in high-grade glioma (HGG), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 24 weeks Progression-Free Survival rate. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03925246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925246.